Synthetic Antibodies - The Emerging Field of "Aptamers" in Diagnostics and Drug Discovery
Presented At: LabRoots - Drug Discovery Virtual Event 2019 Presented By: G. Thomas Caltagirone, PhD - President & CEO, Aptagen, LLC Speaker Biography: Dr. Caltagirone is the President & CEO of Aptagen and has over 25 years of research and business experience in start-ups. A native of York, PA, he began his studies at the University of the Sciences in Philadelphia followed by a Ph.D. in neuroscience from Drexel University. He completed his thesis on "Proton-Sensitive Ribozyme Switches with Molecular Memory" at Yale University, and has several patents and publications under his name. Webinar: Synthetic Antibodies - The Emerging Field of "Aptamers" in Diagnostics and Drug Discovery Webinar Abstract: An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, biomarkers, cells, and tissues. Typical aptamer affinities are in the nanomolar to picomolar range for several target types. However, unlike the traditional antibody, aptamers have impressive specificities against target antigens, thereby eliminating cross-reactivity with closely related targets and avoiding false-positive results. A classic example is an aptamer that exhibits greater than 10,000-fold binding affinity for theophylline over caffeine, which differ from one another in structure by only a single methyl group. Additional benefits of aptamers include: manufacturing costs and time are all lower compared to that of monoclonal antibody production. Once the aptamer (nucleic acid) sequence is known, the aptamer can be easily synthesized using a DNA (oligo) synthesizer. These aptamer oligos are easy to label with reporters, enzymes, or fluorescent tags. In addition, aptamers can be engineered into molecular switches or apta-switches for signal generation in a drug discovery-based assay or to produce an output in a diagnostic test. Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-even...) 2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-even...) 3. Click Here to get your PACE (Expiration date – February 27, 2021 10:30 AM) – https://www.labroots.com/credit/pace-... LabRoots on Social: Facebook: / labrootsinc Twitter: / labroots LinkedIn: / labroots Instagram: / labrootsinc Pinterest: / labroots SnapChat: labroots_inc

Targeted delivery using aptamers

Aptamers in Drug Development: From Biomarker Discovery to Targeted Drug Delivery..

Keynote Presentation: Nucleic Acid Detection with CRISPR Diagnostics

Donor Profiling and Cell Isolation for Scalable Cell and Gene Therapy Manufacturing

Explore the Medical Laboratory Sciences Grad Program: Live Webinar Recap

The World's Most Important Machine

Next Generation Sequencing 1: Overview - Eric Chow (UCSF)

ACLS Drugs Review with Nurse Eunice 📚💉

Aptamers in Brain research: Design, Molecule Detection, Disease Applications | Nako Nakatsuka

Anna Marie Pyle (Yale U./HHMI) Part 1: RNA Structure

AI Is Creating A Rare Opportunity For Investors. How Jim Roppel Is Playing It. | Investing With IBD

AI Workshop 6 - GenAI for Research

Polymerase Chain Reaction (PCR): the not-so-basics - Part 1

Addiction Neuroscience 101

Archive: Application of Aptamers in the Clinical Laboratory - Geoffrey Baird, MD, PhD

Historian Timothy Snyder on ENDING Trump Nightmare FOR GOOD | PoliticsGirl

Design of microRNA therapeutics

How to Build Endurance | Huberman Lab Essentials

Jfrog | Jfrog Artifactory | Jfrog Artifactory Tutorial | Artifactory Tutorial | Intellipaat
![Understand AI in 14 minutes – with Anthropic's Chloe Lubinski [ARC 2026]](https://i.ytimg.com/vi/aBUniZHgCnE/hqdefault.jpg?sqp=-oaymwEjCNACELwBSFryq4qpAxUIARUAAAAAGAElAADIQj0AgKJDeAE=&rs=AOn4CLCyQJdkwlip_867U0IUOY4wCWZJ0g)
